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Abstract
Background: The aim of this study was to evaluate the efficacy and safety of topical ganciclovir 0.15 % gel in the
management of patients with cytomegalovirus (CMV) anterior uveitis.
Results: This was a retrospective cohort study of the disease course of 31 patients (33 eyes) with aqueous
polymerase chain reaction (PCR) positive for CMV. Data from a total of 160 episodes of anterior uveitis flare
for 20 years, dating from December 1992 to December 2012, was collected. All patients were treated with
concomitant topical anti-inflammatory medication. The disease course of each eye was analysed before and
after the use of topical ganciclovir 0.15 %. The mean age at initial presentation of anterior uveitis was 57.5 ±
12.6 years. Twenty-eight (90.3 %) patients were Chinese. Patients on topical ganciclovir gel had a statistically
significant fewer episodes of uveitis flare per person year (median −0.88 episodes/person years, p = 0.029). The
time-to-quiescence was not significantly affected by topical ganciclovir use (median −1.25 days, p = 0.610). In
the survival analysis using the Cox regression model, the use of topical ganciclovir was associated with a lower
risk of recurrence, but this was not statistically significant (hazard ratio = 0.857, 95 % CI 0.543–1.36, p = 0.511).
The overall median time-to-recurrence was 290 days (95 % CI 113 to 274 days) and 164 days (125 to 404 days)
(p = 0.492), with and without topical ganciclovir, respectively.
Conclusions: Topical ganciclovir may be beneficial in reducing the frequency of recurrence in patients with CMV
anterior uveitis, but it was not statistically associated with prolonging the time-to-recurrence. The time-to-quiescence
was also not significantly affected by topical ganciclovir. Prospective studies with a larger number of patients would be
required to verify our findings.
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Background
Cytomegalovirus (CMV) had been postulated as an etio-
logical cause of hypertensive uveitis since the 1980s [1].
It was only in the past decade with the increased avail-
ability of polymerase chain reaction (PCR) that viruses
have been confirmed as the aetiology of what was previ-
ously considered to be idiopathic anterior uveitis [2, 3].
The clinical manifestations of CMV infection of the
anterior segment of the eye include anterior chamber in-
flammation, keratic precipitates (KPs), elevated intraocu-
lar pressure (IOP), and corneal endothelial cell damage
[4]. The diagnosis of CMV anterior uveitis was by PCR
of aqueous humour obtained via anterior chamber
paracentesis.
In the treatment of patients with this disease entity,
the discovery of this viral aetiology has lead to the possi-
bility of including anti-viral medications to the treatment
regime in addition to topical anti-inflammatory and
topical anti-glaucoma medications Ganciclovir is a
potent inhibitor of herpes viruses, including CMV. It is a
nucleoside analogue that suppresses the replication of
herpes viruses [5, 6] and functions as a virustatic agent.
Ganciclovir has been used systemically, in the form of
intravitreal injections and implants for CMV infections
of the eye [7–9].
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More recently, topical ganciclovir has been shown to
be effective against herpetic keratitis [10]. Topical appli-
cation of ganciclovir has also been shown to penetrate
the corneal stroma and achieve therapeutic levels in the
aqueous humour [11]. It has been used in the treatment
of CMV anterior uveitis, but its effectiveness has been
reported in only a limited number of studies [4, 9, 12].
We aim to evaluate the safety and efficacy of topical
ganciclovir gel 0.15 % (Virgan, Laboratoires Théa, France)
in the treatment of CMV anterior uveitis patients at a
tertiary referral eye care centre in Singapore.
Methods
We performed a retrospective chart review of patients
with CMV anterior uveitis who were treated at our
centre, from 1992 to 2012. This study was approved
by the institutional review board (National Healthcare
Group Domain Specific). We included eyes with clinical
signs suggestive of CMV anterior uveitis including senti-
nel keratic precipitates, mild anterior uveitis, and high
intraocular pressure. The eyes included were also posi-
tive for CMV on PCR from aqueous fluid and negative for
herpes simplex virus (HSV), Varicella zoster virus (VZV),
and Toxoplasma gondii. We excluded eyes with corneal
involvement of the disease such as endotheliitis and cor-
neal edema and eyes with CMV retinitis.
Topical ganciclovir 0.15 % gel was first made available
at our centre in March 2010. We compared the disease
course of each eye inflicted with CMV anterior uveitis
before and after ganciclovir 0.15 % gel was added to the
treatment regime. All the patients with positive PCR for
CMV after March 2010 had treatment with topical
ganciclovir 0.15 %.
Response to treatment or quiescence was defined as
the reduction in anterior chamber (AC) inflammation to
nil, with no episodes of flare-up of uveitis, which was
defined as an increase in AC activity by one step. The
primary outcome measures were time-to-quiescence,
time-to-recurrence, and number of uveitis flare-ups per
person year. Time-to-quiescence was defined as the dur-
ation from the presentation/recurrence of hypertensive
uveitis to the time when zero cells were noted in the
AC, as defined by the Standardization of Uveitis Nomen-
clature (SUN) Working Group [13]. Time-to-recurrence
was defined as the duration between the start of one
episode of hypertensive uveitis to the next episode. Crude
incidence rates and recurrence rates were calculated, and
comparisons were made for the disease course of each eye
before and after the use of topical ganciclovir.
Patients were initially started on topical ganciclovir
at an intensive frequency of 3 h (six times per day),
tapered based on anterior chamber inflammation over
the course of 3 months, and subsequently kept on long-
term maintenance therapy (three to four times per
day). All patients were concurrently treated with anti-
inflammatory eye drops, in the form of topical steroids,
and also topical anti-glaucoma medications as deemed
necessary by the attending ophthalmologist. Topical
non-steroidal anti-inflammatory drugs (NSAIDs) were
not used in our cohort. None of the patients in this
cohort had oral, intravitreal, or parenteral ganciclovir.
The patients were reviewed weekly for the first month
and then monthly thereafter, with more frequent reviews
as necessary.
Data analyses were performed with Stata 11.0 (StataCorp
LP, College Station, Texas, USA). Wilcoxon signed-rank
test was used when comparing the differences within each
eye while on and off topical ganciclovir. For survival ana-
lysis comparing the recurrences in eyes with and without
topical ganciclovir treatment, a Cox regression model was
constructed to analyse recurrences and to demonstrate
efficacy of topical ganciclovir. Only the first eye which pre-
sented with CMV anterior uveitis in patients with bilateral
disease was included in the survival analysis.
Results
Data from 33 eyes of 31 patients were obtained. The mean
age of these patients was 57.5 ± 12.6 years. The majority of
our patients were male (74.2 %). The demographic charac-
teristics of our patients are summarized in Table 1.
There were a total of 160 episodes of flare-ups of
anterior uveitis in these patients. One hundred and
seventeen episodes (36,440 days) were not treated with
topical ganciclovir, while 43 episodes (11,750 days) were
treated with topical ganciclovir. Patients were on main-
tenance treatment with topical ganciclovir for an average
of 9.1 ± 2.5 months for each episode of uveitis flare.
With topical ganciclovir use, there was a significant
reduction in the median number of episodes of anterior
uveitis recurrence per person year of −0.88 episodes per
person year (episodes/PY) (p = 0.029). The median change
of time-to-quiescence per episode of uveitis was −1.25 days
(p = 0.610), and the median change of time-to-recurrence
per episode of uveitis was −143.75 days (p = 0.285). These
results are represented in Table 2.
Table 1 Demographics of patients with CMV anterior uveitis
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In the survival analysis using Cox regression model,
topical ganciclovir was associated with a lower risk of re-
currence but this was not statistically significant (hazard
ratio = 0.857, 95 % CI 0.543–1.36, p = 0.511). The overall
median time-to-recurrence, as represented in Fig. 1, was
290 days (95 % CI 113 to 274 days) with and 164 days
(125 to 404 days) (p = 0.492) without topical ganciclovir
use, respectively.
There were no significant side effects such as ocular
discomfort from topical ganciclovir application or ocular
surface toxicity noted in our patients.
Of the 33 eyes, 7 (21.2 %) developed raised IOP not
controlled with maximum topical glaucoma medications
and required glaucoma surgery. Four of the 7 eyes
(57.14 %) had to undergo glaucoma surgery despite hav-
ing been started on treatment with ganciclovir ointment.
None of the patients developed corneal decompensation
secondary to CMV anterior uveitis.
Discussion
CMV anterior uveitis can result in significant visual mor-
bidity due to its recurrent or chronic disease course [9].
The main complications include cataract formation, cor-
neal decompensation, secondary open angle, and steroid
induced glaucoma [14]. This disease entity affects the
anterior segment of the eye only. Posterior segment in-
volvement is not typically reported with CMV anterior
uveitis. In a case series of five immunocompetent
patients from Europe with positive CMV on anterior
chamber paracentesis, none of them also had posterior
segment involvement [15]. We have earlier reported
clinical characteristics of 16 patients of CMV anterior
uveitis in immunocompetent patients without any pos-
terior segment involvement [16].
The role of topical therapy is pertinent as the disease
is limited to the anterior segment without any posterior
segment involvement. Chee and Jap reported that the
use of topical ganciclovir in CMV anterior uveitis
patients resulted in moderate response rates and lower
recurrence rates as compared with systemic and implant
ganciclovir [9]. Chronic prophylaxis was needed as hy-
pertensive uveitis recurred after cessation of ganciclovir
[8]. However, the duration of long-term therapy and its
implications have not been reported in literature.
A recent report of 106 patients of CMV corneal
endotheliitis by the Japanese corneal endotheliitis study
group illustrated the clinical characteristics and treat-
ment outcome for this type of viral uveitis [17]. The
authors reported use of topical ganciclovir in 82 (75.2 %)
eyes and systemic anti-CMV therapy in 74 (67.9 %) eyes.
There were 52 (47.7 %) eyes treated with both systemic
and topical anti-CMV drugs, and the results suggested
that combination therapy is more beneficial. A signifi-
cant number of patients (36 %) had recurrence of in-
flammation while on anti-CMV therapy. However, it was
not analysed with duration of therapy [17].
The findings from our Cox regression model, in particu-
lar, the intra-eye comparison of the median number of
episodes of anterior uveitis recurrence per person year
with and without topical ganciclovir use and the overall
median time-to-recurrence as represented in Fig. 1, sug-
gested that the use of topical ganciclovir could reduce the
number of episodes of uveitis recurrence (p = 0.029) but
was not statistically associated with either the reduced risk
of recurrence (p = 0.511) or prolonging the time-to-
recurrence (p = 0.492). The time-to-quiescence was also
not affected. These results contradict the findings of
earlier reports and suggest that even though topical ganci-
clovir can reduce the number of recurrences of flare-up of
uveitis in a PCR proven case of CMV anterior uveitis, it
does not necessarily prolong the time-to-recurrence. This
is the first ever reported Cox regression model for CMV
anterior uveitis topical ganciclovir use. This model allowed
us to study the recurrences over a period of time in person
years, which is significant in the context of CMV anterior
uveitis where there is no evidence in literature about long-
term maintenance therapy or the safety and efficacy of
topical ganciclovir as anti-CMV therapy.
Table 2 Comparison of median differences between Virgan use
and no Virgan use
Virgan on vs Virgan off: Median IQR p value
No. of episodes of uveitis








Fig. 1 Kaplan-Meier survival estimates with and without topical
ganciclovir
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The reduction in the median number of episodes of
anterior uveitis recurrence of 0.88 episodes per person
years may seem insignificant, but its potential cumula-
tive effect and role in reducing glaucomatous damage or
corneal decompensation in prolonging if not preventing
the onset of sight threatening complications can be
further explored in larger multicenter studies with ex-
panded case definition of disease quiescence. However,
patients have to be kept on maintenance therapy chron-
ically. Repeated episodes of uveitis flare when patients
were off topical ganciclovir may still result in progres-
sion of glaucomatous damage, which may necessitate
glaucoma surgery.
Topical ganciclovir application is convenient and non-
invasive as compared with intravitreal injections, im-
plants, and systemic intravenous administration. There
are no procedural risks involved. More importantly, the
potential adverse effects of systemic ganciclovir and the
ganciclovir implant limit their use on a long-term basis.
There is no reported need for monitoring of full blood
count and serum creatinine levels as compared to intra-
venous ganciclovir use.
This was a retrospective non-randomized study, and
the study cohort was relatively small. The results need
to be interpreted with caution and validated by larger
trials. As data from this study was collected from 1992,
the change in the type of topical steroids used over time
could be a drawback of this study. Spersadexoline
(dexamethasone 0.1 %, chloramphenicol 0.5 %, tetrahy-
drozoline HCl 0.025 %) was used before the availability
of prednisolone acetate 1 % (Allergan, Irvine, USA).
Conclusions
In conclusion, topical ganciclovir 0.15 % gel has a potential
role in reducing episodes of recurrences in CMV anterior
uveitis on long-term maintenance therapy. Reduction in
number of recurrences per person year post treatment
may be due to shorter follow-up period post treatment,
and the heterogeneity in follow-up duration was identified
as one of the limitations of this retrospective analysis.
Hence, further prospective multicenter studies, with a lar-
ger number of patients required, to further explore the
findings is needed to compare the safety and efficacy of
topical gel with oral or intravitreal ganciclovir. Like her-
petic keratouveitis, longitudinal cross-sectional studies are
warranted for CMV anterior uveitis to determine the
duration of long-term maintenance therapy.
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